Keyword Analysis & Research: daratumumab
Keyword Research: People who searched daratumumab also searched
Search Results related to daratumumab on Search Engine
-
Daratumumab - Wikipedia
https://en.wikipedia.org/wiki/Daratumumab
webDaratumumab, sold under the brand name Darzalex, is an anti-cancer monoclonal antibody medication. It binds to CD38 , [3] which is overexpressed in multiple myeloma cells. [4] Daratumumab was originally developed by Genmab , but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech , which ...
DA: 47 PA: 57 MOZ Rank: 45
-
Daratumumab - NCI - National Cancer Institute
https://www.cancer.gov/about-cancer/treatment/drugs/daratumumab
webDaratumumab is approved to be used alone or with other drugs to treat: Multiple myeloma. It is used: In adults with newly diagnosed disease. It is used: With lenalidomide and dexamethasone or with bortezomib, melphalan, and prednisone in patients who cannot receive an autologous stem cell transplant.
DA: 16 PA: 10 MOZ Rank: 73
-
Daratumumab Uses, Side Effects & Warnings - Drugs.com
https://www.drugs.com/mtm/daratumumab.html
webOct 27, 2023 · Daratumumab is a monoclonal antibody that blocks a certain protein in the body that can affect tumor cell growth. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Daratumumab is used to treat multiple myeloma (bone marrow cancer).
DA: 55 PA: 99 MOZ Rank: 13
-
Daratumumab (Intravenous Route) Description and Brand Names - Mayo Clinic
https://www.mayoclinic.org/drugs-supplements/daratumumab-intravenous-route/description/drg-20165230
webFeb 1, 2024 · Descriptions. Daratumumab injection is used alone or together with other medicines to treat multiple myeloma (a type of bone marrow cancer). It is used alone in patients who have received at least 3 prior treatments that did not work well, including a proteasome inhibitor and an immunomodulatory agent, or who did not respond to both a ...
DA: 72 PA: 74 MOZ Rank: 91
-
Darzalex (Daratumumab) | International Myeloma Foundation
https://www.myeloma.org/darzalex-daratumumab
webAug 24, 2021 · Darzalex (daratumumab) is a highly effective drug used to treat multiple myeloma. Read about who is a candidate, side effects, special warnings. Darzalex is the first FDA-approved monoclonal antibody that targets …
DA: 65 PA: 96 MOZ Rank: 11
-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone …
https://www.nejm.org/doi/full/10.1056/NEJMoa2312054
webDec 12, 2023 · Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide,...
DA: 49 PA: 15 MOZ Rank: 63
-
Daratumumab (DARZALEX) | FDA
https://www.fda.gov/drugs/resources-information-approved-drugs/daratumumab-darzalex
webDaratumumab (DARZALEX) Share. On November 21, 2016, the U.S. Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with lenalidomide and...
DA: 72 PA: 87 MOZ Rank: 15
-
Daratumumab for post-ASCT maintenance treatment of myeloma
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00490-3/fulltext
webSep 13, 2021 · Daratumumab for post-ASCT maintenance treatment of myeloma. Daratumumab, a potent CD38-directed monoclonal antibody, has veritably transformed the treatment landscape of multiple myeloma. 1. CASSIOPEIA, a two-part, phase 3 trial, has brought daratumumab to the forefront of efforts aimed at improving outcome for …
DA: 47 PA: 70 MOZ Rank: 9
-
Daratumumab: A review of current indications and future directions
https://www.sciencedirect.com/science/article/pii/S0093775422000082
webJan 20, 2022 · Daratumumab is a human IgG1 kappa monoclonal antibody which has been shown to be effective as monotherapy, as well as in combination regimens, for the treatment of both newly diagnosed MM (NDMM), and relapsed/refractory MM (RRMM).
DA: 33 PA: 66 MOZ Rank: 93
-
Daratumumab: Uses, Interactions, Mechanism of Action
https://go.drugbank.com/drugs/DB09331
webNov 18, 2015 · Daratumumab. DrugBank Accession Number. DB09331. Background. Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. 1 It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. 5.
DA: 45 PA: 38 MOZ Rank: 83